Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.67 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.66 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398931 | 1.00 | CRBN (0.67) | CRBNDDB1IKZF2CSNK1A1 | |
| SCHEMBL18270946 | 0.93 | CRBN (0.58) | CRBNDDB1IKZF2CSNK1A1 | |
| SCHEMBL1398905 | 0.91 | CRBN (0.67) | CRBNDDB1 | |
| SCHEMBL29058875 | 0.84 | CRBN (0.61) | CRBNDDB1IKZF2 | |
| SCHEMBL29528664 | 0.82 | CRBN (0.73) | CRBNDDB1 | |
| SCHEMBL28667428 | 0.82 | CRBN (0.73) | CRBNDDB1 | |
| SCHEMBL29482963 | 0.82 | CRBN (0.75) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL20765391 | 0.82 | CRBN (0.75) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL61557 | 0.81 | CRBN (0.70) | CRBNDDB1IKZF2CSNK1A1 | |
| SCHEMBL23298653 | 0.81 | CRBN (0.73) | CRBNIKZF2CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116457344-B | Low molecular weight protein degradation agent and application thereof | 凯普托尔治疗学股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4618755-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4584259-A1 | CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS | Innovo Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-115335373-B | Compounds and uses thereof | 福宏治疗公司 | 2025-05-20 | — | — | CN | disclosed |
| US-12291522-B2 | Galectin-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-06 | — | — | US | disclosed |
| WO-2024258789-A1 | MODULATORS OF CDK2 AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| CN-115666575-B | Compounds and uses thereof | 福宏治疗公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-118076607-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024107746-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-115304606-B | Degradation agent for simultaneously targeting BTK and GSPT proteins | 清华大学 | 2024-04-19 | — | — | CN | disclosed |
| WO-2024054832-A1 | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-116457344-A | Low molecular weight protein degradation agent and application thereof | 凯普托尔治疗学股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-4157833-A1 | GALECTIN-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2023-04-05 | — | — | EP | disclosed |
| CN-115768768-A | Galectin-3 inhibitors | 百时美施贵宝公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-115666575-A | Compound and use thereof | 福宏治疗公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115335373-A | Compound and use thereof | 福宏治疗公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115304606-A | Degradation agent for simultaneously targeting BTK and GSPT1 proteins | 清华大学 | 2022-11-08 | — | — | CN | disclosed |
| EP-4077319-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | Calico Life Sciences LLC (US) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12291522-B2 | Galectin-3 inhibitors | LGALS3, LGALS1, LGALS3BP | CRBN 3037/4885DDB1 2211/4885IKZF2 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.